ArticlePloS one2025
Genomic characteristics of Lacticaseibacillus rhamnosus strains isolated from blood.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lacticaseibacillus rhamnosus is widely recognized for its health-promoting properties, which have led to its broad application in the production of food and dietary supplements. Nevertheless, although rare and typically limited to patients with underlying conditions, adverse effects have also been reported. In this study, we sequenced and characterized the genomes of seven L. rhamnosus strains isolated from blood. Using a hybrid approach that combined Illumina and Oxford Nanopore technologies, we obtained complete genomes ranging from 2.96 to 3.13 Mb, with a GC content of 46.7-46.8%. Comparative analyses with publicly available L. rhamnosus genomes revealed that these isolates were genetically related to strains from highly diverse origins, including plants, dairy products, dietary supplements, the gastrointestinal and genitourinary tracts, as well as blood and other clinical samples from geographically distant regions. Importantly, neither core genome multilocus sequence typing (cgMLST) nor prophage and CRISPR module analyses indicated similarity to the widely used probiotic strain L. rhamnosus GG. Gene-based analysis identified determinants associated with bacteriocin production, adhesion, health-promoting traits, and potential pathogenicity of the strains. Notably, several genes linked to probiotic functions also overlapped with virulence factors found in pathogenic microorganisms. These findings demonstrate the genomic diversity of L. rhamnosus blood isolates and highlight the dual role of certain genetic determinants, underlining the importance of careful strain-level evaluation when selecting L. rhamnosus strains for probiotic use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.